"TWILIGHT-ACS: Ticagrelor Monotherapy Beneficial In PCI For ACS" - Erik Swain
Among patients with ACS who underwent PCI, ticagrelor monotherapy reduced bleeding risk compared with dual antiplatelet therapy, with no additional ischemic risk, according to new data from the TWILIGHT study presented at the American Heart Association Scientific Sessions. In the present TWILIGHT-ACS substudy of 5,763 patients from TWILIGHT with non-ST-segment elevation ACS, the results were consistent with the main study, said Usman Baber, MD, MS, assistant professor of medicine at Icahn School of Medicine at Mount Sinai. He added, “We found that the effect of ticagrelor monotherapy was uniform across different levels of risk, and the results were consistent regardless if you presented with unstable angina or non-STEMI.”
— Usman Baber, MD, MS, Assistant Professor, Medicine, Cardiology, Icahn School of Medicine at Mount Sinai
Additional coverage: Medscape; Medpage Today; MD Magazine
Blocking a Little-Known Protein May Offer New Hope for Devastating Lung Disease
Jul 15, 2025 View All Press Releases
Mount Sinai Surgeons Perform First Heart-Liver-Kidney Transplants in New York State
May 20, 2025 View All Press Releases
After a Heart Attack, the Heart Signals to the Brain to Increase Sleep to Promote Healing
Oct 30, 2024 View All Press Releases